

We Claim:

5 1. A method for treating vascular endothelial growth factor mediated vascular disorders, which comprises, administering a pharmaceutically effective amount of amfenac.

10 2. The method of Claim 1 wherein the disorder is selected from the group consisting of exudative age related macular degeneration, proliferative diabetic retinopathy, retinal vein occlusion, proliferative vitreoretinopathy, neovascular glaucoma, corneal angiogenesis, retinal microvasculopathy, and retinal (macular) edema.

15 3. A method for treating vascular endothelial growth factor mediated vascular disorders, which comprises, administering a pharmaceutically effective amount of nepafenac.

20 4. The method of Claim 3 wherein the disorder is selected from the group consisting of exudative age related macular degeneration, proliferative diabetic retinopathy, retinal vein occlusion, proliferative vitreoretinopathy, neovascular glaucoma, corneal angiogenesis, retinal microvasculopathy, and retinal (macular) edema.

25 5. The method of Claim 1 wherein the disorder is an ophthalmic disorder.

6. The method of Claim 3 wherein the disorder is an ophthalmic disorder.

7. The method of Claim 2 wherein the disorder is retinal (macular) edema.

30 8. The method of Claim 4 wherein the disorder is retinal (macular) edema.

9. The method of Claim 2 wherein the disorder is proliferative diabetic retinopathy.

35 10. The method of Claim 4 wherein the disorder is proliferative diabetic retinopathy.